


COMPANY OVERVIEW

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant *Staph aureus* (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) *Pseudomonas aeruginosa*.



CONTRACT CORPORATION

28 Wells Avenue
3rd Floor
Yonkers, NY 10701
US

RECENT NEWS

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

Oct 16 2023, 7:30 AM EDT

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

Sep 19 2023, 8:30 AM EDT

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

Sep 18 2023, 7:30 AM EDT

STOCK OVERVIEW

Symbol	CFRX
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week Range	\$ - \$

INVESTOR RELATIONS

Michael Messinger
T: 914-207-2300
mmessinger@contrafect.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

